Cargando…

COVID-19: Insights into Potential Vaccines

People around the world ushered in the new year 2021 with a fear of COVID-19, as family members have lost their loved ones to the disease. Millions of people have been infected, and the livelihood of many has been jeopardized due to the pandemic. Pharmaceutical companies are racing against time to d...

Descripción completa

Detalles Bibliográficos
Autores principales: Loo, Ke-Yan, Letchumanan, Vengadesh, Ser, Hooi-Leng, Teoh, Siew Li, Law, Jodi Woan-Fei, Tan, Loh Teng-Hern, Ab Mutalib, Nurul-Syakima, Chan, Kok-Gan, Lee, Learn-Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001762/
https://www.ncbi.nlm.nih.gov/pubmed/33804162
http://dx.doi.org/10.3390/microorganisms9030605
_version_ 1783671305974841344
author Loo, Ke-Yan
Letchumanan, Vengadesh
Ser, Hooi-Leng
Teoh, Siew Li
Law, Jodi Woan-Fei
Tan, Loh Teng-Hern
Ab Mutalib, Nurul-Syakima
Chan, Kok-Gan
Lee, Learn-Han
author_facet Loo, Ke-Yan
Letchumanan, Vengadesh
Ser, Hooi-Leng
Teoh, Siew Li
Law, Jodi Woan-Fei
Tan, Loh Teng-Hern
Ab Mutalib, Nurul-Syakima
Chan, Kok-Gan
Lee, Learn-Han
author_sort Loo, Ke-Yan
collection PubMed
description People around the world ushered in the new year 2021 with a fear of COVID-19, as family members have lost their loved ones to the disease. Millions of people have been infected, and the livelihood of many has been jeopardized due to the pandemic. Pharmaceutical companies are racing against time to develop an effective vaccine to protect against COVID-19. Researchers have developed various types of candidate vaccines with the release of the genetic sequence of the SARS-CoV-2 virus in January. These include inactivated viral vaccines, protein subunit vaccines, mRNA vaccines, and recombinant viral vector vaccines. To date, several vaccines have been authorized for emergency use and they have been administered in countries across the globe. Meanwhile, there are also vaccine candidates in Phase III clinical trials awaiting results and approval from authorities. These candidates have shown positive results in the previous stages of the trials, whereby they could induce an immune response with minimal side effects in the participants. This review aims to discuss the different vaccine platforms and the clinical trials of the candidate vaccines.
format Online
Article
Text
id pubmed-8001762
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80017622021-03-28 COVID-19: Insights into Potential Vaccines Loo, Ke-Yan Letchumanan, Vengadesh Ser, Hooi-Leng Teoh, Siew Li Law, Jodi Woan-Fei Tan, Loh Teng-Hern Ab Mutalib, Nurul-Syakima Chan, Kok-Gan Lee, Learn-Han Microorganisms Review People around the world ushered in the new year 2021 with a fear of COVID-19, as family members have lost their loved ones to the disease. Millions of people have been infected, and the livelihood of many has been jeopardized due to the pandemic. Pharmaceutical companies are racing against time to develop an effective vaccine to protect against COVID-19. Researchers have developed various types of candidate vaccines with the release of the genetic sequence of the SARS-CoV-2 virus in January. These include inactivated viral vaccines, protein subunit vaccines, mRNA vaccines, and recombinant viral vector vaccines. To date, several vaccines have been authorized for emergency use and they have been administered in countries across the globe. Meanwhile, there are also vaccine candidates in Phase III clinical trials awaiting results and approval from authorities. These candidates have shown positive results in the previous stages of the trials, whereby they could induce an immune response with minimal side effects in the participants. This review aims to discuss the different vaccine platforms and the clinical trials of the candidate vaccines. MDPI 2021-03-15 /pmc/articles/PMC8001762/ /pubmed/33804162 http://dx.doi.org/10.3390/microorganisms9030605 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Review
Loo, Ke-Yan
Letchumanan, Vengadesh
Ser, Hooi-Leng
Teoh, Siew Li
Law, Jodi Woan-Fei
Tan, Loh Teng-Hern
Ab Mutalib, Nurul-Syakima
Chan, Kok-Gan
Lee, Learn-Han
COVID-19: Insights into Potential Vaccines
title COVID-19: Insights into Potential Vaccines
title_full COVID-19: Insights into Potential Vaccines
title_fullStr COVID-19: Insights into Potential Vaccines
title_full_unstemmed COVID-19: Insights into Potential Vaccines
title_short COVID-19: Insights into Potential Vaccines
title_sort covid-19: insights into potential vaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001762/
https://www.ncbi.nlm.nih.gov/pubmed/33804162
http://dx.doi.org/10.3390/microorganisms9030605
work_keys_str_mv AT lookeyan covid19insightsintopotentialvaccines
AT letchumananvengadesh covid19insightsintopotentialvaccines
AT serhooileng covid19insightsintopotentialvaccines
AT teohsiewli covid19insightsintopotentialvaccines
AT lawjodiwoanfei covid19insightsintopotentialvaccines
AT tanlohtenghern covid19insightsintopotentialvaccines
AT abmutalibnurulsyakima covid19insightsintopotentialvaccines
AT chankokgan covid19insightsintopotentialvaccines
AT leelearnhan covid19insightsintopotentialvaccines